Tinset indications
Oral
Allergic conditions
Adult: As anhydrous substance: 30 mg bid.
Child: As anhydrous substance: Initially, 0.5 mg/kg bid. Optimal dose: 0.5-1 mg/kg bid.
Hepatic impairment: Initiate at 50% of the normal dose.
Tinset description
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
Tinset dosage
Oral
Allergic conditions
Adult: As anhydrous substance: 30 mg bid.
Child: As anhydrous substance: Initially, 0.5 mg/kg bid. Optimal dose: 0.5-1 mg/kg bid.
Hepatic impairment: Initiate at 50% of the normal dose.
Tinset interactions
May enhance effects of CNS depressants e.g. alcohol, barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives and tranquillizers. Anticholinergic effects of atropine, TCAs, MAOIs may be enhanced. May mask signs of ototoxicity caused by aminoglycosides.
Tinset side effects
Sedation, inability to concentrate, lassitude, dizziness, hypotension, muscular weakness, incoordination. Nausea, vomiting, diarrhoea or constipation, epigastric pain. Headache, blurred vision, tinnitus, elation or depression, irritability, nightmares, anorexia, urinary retention, dry mouth, chest tightness, dysuria and tingling. Rash, urticaria. Agranulocytosis, haemolytic anaemia. Increased appetite, wt gain. Convulsions, increased transaminase, hepatitis. Dyskinetic neurological reactions (infants and young children).
Potentially Fatal: Anaphylactoid reactions, angioedema.
Tinset contraindications
Tinset should not be given to patients who are hypersensitive to erythromycin, sulfonamides, or any component of the formulation, who have hepatic dysfunction, and porphyria. It is containdicated in infants of less than 2 months of age.
Tinset can not be used concurrently with pimozide or cisapride.
Active ingredient matches for Tinset:
Oxatomide in Argentina, Chile, Costa Rica, Cyprus, Dominican Republic, Egypt, El Salvador, France, Greece, Guatemala, Honduras, Indonesia, Italy, Jordan, Lebanon, Luxembourg, Mexico, Netherlands, Nicaragua, Panama, Portugal, Saudi Arabia, South Africa, Sudan, Taiwan, Thailand, United Arab Emirates, Yemen.
| Unit description / dosage (Manufacturer) | Price, USD |
| Gel; Topical; Oxatomide Hydrate 5% | |
| Suspension; Oral; Oxatomide 2.5 mg / ml | |
| Tablet; Oral; Oxatomide 30 mg | |
| Tinset 30 mg x 250's | |
| Tinset 30 mg x 25 x 10's | |
| Tinset 30 mg x 50 x 10's | |
| Tinset 30 mg x 50's | $ 18.41 |
List of Tinset substitutes (brand and generic names): | |
| Iwatomid 2% (Japan) | |
| Laiceltec (Japan) | |
| Mectect (Japan) | |
| Okilot (Japan) | |
| Okilot 2% (Japan) | |
| Oxamide (Taiwan) | |
| Oxamide 30 mg x 100's | |
| Oxamide 30 mg x 500's | |
| Oxatect (Japan) | |
| Oxatokey (Spain) | |
| Oxatomide (Argentina, Greece, Indonesia, Italy, Netherlands, South Africa, South Korea, Taiwan, Thailand) | |
| Oxatomide 0.2% (Japan) | |
|
sponsored
| |
| Oxatomide 2% (Japan) | |
| Oxatomide 2% Iwaki (Japan) | |
| Oxatomide 2% Nichi-iko (Japan) | |
| Oxatomide 2% Taiyo (Japan) | |
| Oxatomide DS 2% (Japan) | |
| Oxatomide EMEC (Japan) | |
| Oxatomide Iwaki (Japan) | |
| Oxatomide Kunihiro (Japan) | |
| Oxatomide Nichi-iko (Japan) | |
| Oxatomide Sannova (Japan) | |
| Oxatomide Taiyo (Japan) | |
| Oxatomide Tanabe (Japan) | |
| Oxatomide ZE (Japan) | |
| Oxatomide Zensei (Japan) | |
| Oxatowa (Japan) | |
| Oxatowa 2% (Japan) | |
| Oxatowa DS 2% (Japan) | |
| Oxleti (Spain) | |
| Oxtin (Indonesia) | |
| Oxtin 30 mg x 5 x 10's (Guardian) | $ 13.95 |
| Pepecin (Japan) | |
| Pepecin 2% (Japan) | |
| Sekitarl (Japan) | |
| Sekitarl 0.2% (Japan) | |
| Selmalen (Japan) | |
| Spaclit (Japan) | |
| Tanzal (Spain) | |
| Taurustan (Japan) | |
| Taurustan DS 2% (Japan) | |
| Ulymin (Taiwan) | |
| Ulymin 30 mg x 100 x 10's | |
| Ulymin 30 mg x 1000's | |
See 59 substitutes for Tinset | |
References
- PubChem. "oxatomide". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Oxatomide". http://www.drugbank.ca/drugs/DB12877 (accessed September 17, 2018).
- DTP/NCI. "oxatomide: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Tinset are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tinset. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the Tinset drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Useful | 1 | 100.0% | |
1 consumer reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive?The below mentioned numbers have been reported by ndrugs.com website users about whether the Tinset drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
| Users | % | ||
|---|---|---|---|
| Expensive | 1 | 100.0% | |
Consumer reported time for results
No survey data has been collected yet3 consumers reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 2 | 66.7% | |
| 6-15 | 1 | 33.3% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
